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Thioacetamide (TA), originally used as a
fungicide, is a potent hepatotoxicant that has
been much studied since the first report ofits
toxic properties (1-4). Earlier literature
(5-8) suggests that an obligate intermediate
metabolite ofTA binds to proteins with the
formation of acetylimidolysine derivatives
(7) responsible for TA-induced hepatotoxic
effects. Accordingly, it was reported that the
hepatotoxic effects ofTA are manifested only
after metabolic conversion to thioacetamide-
S-oxide, which undergoes further oxidative
metabolism to an as yet unidentified toxic
metabolite (7). TA has been reported to
stimulate DNA synthesis and mitosis in the
liver of rats at doses that produce limited
necrosis (9-11). The rise in DNA synthesis
induced by TA has been shown to follow a
time course that is similar to that seen fol-
lowing partial hepatectomy (12). Rats treat-
ed with a single dose of 50 mg/kg TA show
non-neoplastic hepatocellular proliferation
indicated by 3H-thymidine (3H-T) incorpo-
ration and cell cycle progression to mitosis
after administration (9,12-14).
Hepatocellular regeneration and tissue
repair mechanisms have been implicated in
the ultimate outcome of toxicity, after
injury from a variety of structurally and
mechanistically dissimilar chemicals includ-
ing carbon tetrachloride (15-18), aceta-
minophen (14), and thioacetamide (19).
These studies have thus far illustrated
two important biological events. They are
the role oftissue repair in the ultimate out-
come oftoxicityand adynamic coexistence
of the processes of tissue repair and tissue
injury as parallel but opposite biological
responses and the collective influence of
their interaction on the ultimate outcome
oftoxicity.
Intervention with the repair processes
has been reported to result in unrestrained
progression of hepatic injury leading to
hepatic failure and animal death (20,21).
Colchicine (CLC) is a widely used antimi-
totic agent (20-23). A single intraperi-
toneal (ip) administration of CLC (1
mg/kg) results in antimitosis against TA
(11,13) with minimal side effects because
ofvery rapid elimination ofthe compound
(23-25). The objective ofthis studywas to
investigate the effect of colchicine antimi-
tosis in a dose-response paradigm. We
hypothesized that if timely and adequate
tissue repair was indeed the critical underly-
ing mechanism for the nonlethality
observed with the lower six-fold dose-range
of TA (19), then intervention with the
repair response should convert these non-
lethal doses to lethal doses. For this study
we chose two doses of TA (150 and 300
mg/kg) from the 12-fold dose-range report-
ed earlier (19). These two doses were cho-
sen because ofthe accompanying high rates
of tissue repair (19). After conducting
lethality studies in the presence and absence
of colchicine, we carried out further time
course (0-96 hr) studies with the 150
mg/kg TA to quantitate tissue repair and
injury. Colchicine antimitotic intervention
resulted in the abolishment of the tissue
repair response that led to 100% lethality
from an ordinarily nonlethal dose of 150
mg/kgTA. These findings establish that the
key difference between moderately toxic
nonlethal doses and a lethal dose of TA is
the presence or absence, respectively, of
adequate and timely tissue repair response.
Materials and Methods
Male Sprague-Dawley rats (175-225 g, 7-8
weeks of age) were obtained from Harlan
Sprague-Dawley, Inc. (Indianapolis, IN) and
were maintained overwoodchip beddingfree
ofanychemical contaminants for 10 days on
a 12-hr photoperiod in our central animal
facility. A 21 ± 1°C temperature and 50%
relative humidity were maintained at all
times. The animals had free access to water
and normal commercial rat chow (Teklad,
Madison, WI, diet#7001) adlibitum.
Thioacetamide (TA) and [3H-methyl]
thymidine (3H-T, specific activity 1.7
Ci/mmol) were obtained from Sigma
Chemical Co. (St. Louis, MO). The scintil-
lation fluid (Scintiverse SX 16-4) was pur-
chased from Fisher Scientific (Baton Rouge,
LA). All other biochemicals and chemicals
were obtained from Sigma Chemical Co.
After acclimation, rats were divided into
four groups (Table 1). Groups I and II
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[ 150 mg/kg
M 150mglkg + CLC Table 1. Protocol to studythe effect of antimitosis
in the dose-response paradigm
TA Saline Colchicine
Groups (mg/kg) (1 mVkg) (1 mg/kg)
No.of %
Rats Survival
1508a + - 5 100
11 150a - + 5 0
il 300b + - 5 100
IV 300b - + 5 0
aColchicine was administered 30 and 42 hr after
TA (150 mg/kg).
bColchicine was administered 42 hr after TA (300
mg/kg).
*Route of administration for both the doses and
vehicle-treated groups was ip. Thioacetamide
was dissolved in vehicle (normal saline, 1 mI/kg).
Rats were observed for 14 days daily. All deaths
occured between 4-6 days after treatment. + and
- indicate the presence and the absence of the
stated treatments respectively.
received 150 mg/kg TA ip at 0 hr. After 30
and 42 hr, Group I received control vehicle
(1 ml/kg) while group II received CLC (1
mg/kg). Groups III and IV received 300
mg/kg TA at 0 hr. After 42 hr, Group III
received control vehicle (1 ml/kg) while
group IV received CLC (1 mg/kg). Rats of
all groups were given normal diet and
water adlibitum during and after treatment
until termination.
One experiment was designed to deter-
mine the lethality ofTA both in the pres-
ence and absence ofCLC treatment in rats
following the administration of each dose
ofTA (150, 300 mg/kg). CLC (1 mg/kg in
normal saline) was administered at 30 and
42 hr (6 hr prior to peak S-phase activities
at 36 and 48 hr) following the administra-
tion of 150 mg/kg TA, while CLC (1
mg/kg in normal saline) was administered
42 hr (6 hr prior to peak stimulation ofcell
division) following treatment with 300
mg/kg TA. The respective controls received
normal saline (1 ml/kg) at the respective
times. The rats were observed twice daily
for 14 days and survival/lethality was
recorded in each group.
Blood was collected from the dorsal
aorta of rats under diethyl ether anesthesia
at 0, 12, 24, 36, 48, 72, and 96 hr after TA
or vehicle administration; the serum was
separated for the estimation of serum
enzymes alanine aminotransferase (ALT,
EC 2.6. 1.2.) and sorbitol dehydrogenase
(SDH, EC 1.1.1.14.) as markers of liver
injury using kit # 59 UV (ALT) and kit #
50 UV (SDH), respectively, from Sigma
Chemical Co.
Portions of liver from each group col-
lected at various periods after TA treatment
were washed with normal saline (0.9%
NaCI), cut into small slices, and fixed in
phosphate buffered 10% formaldehyde solu-
tion for 48 hr. The tissues were then trans-
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Figure 1. Serum alanine aminotransferase (ALT)
was measured as a marker of liver injury over a
time course (0-96 hr) following each treatment.
Male Sprague-Dawley rats (175-225 g) were
divided into two groups. Attime zero both groups
received 150/kg TA in normal saline (1 ml/kg, ip).
Controls received normal saline only (1 ml/kg, ip).
One group received CLC (1 mg/kg, ip) at 30 hr and
42 hr following administration of 150 mg/kg TA.
The other group received normal saline (1 ml/kg)
atthe same time points. Results are expressed as
mean ± SE for four rats in each group at each
time point. Numbers above the error bars indicate
significant differences from control (O hr) and 150
mg/kg TA treated groups, respectively (p.0.05).
Control ALTvalue:54U/I.
ferred to 70% ethyl alcohol until they were
processed. These slices were then embedded
in paraffin after processing. The liver sec-
tions (5 pm thick) were stained with hema-
toxylin-eosin (H&E) for histological exami-
nation underthe light microscope.
3H-T incorporation into hepatonuclear
DNA was measured using the procedure of
Chang and Looney (26) as modified by
Chauveau et al. (27). The DNA content of
the supernatant fraction was estimated by
the diphenylamine reaction (28).
The proliferating cell nuclear antigen
(PCNA) study was done as described by
Greenwell et al. (29) and as reported earli-
er (14,19).
Mean ± SEM were calculated for all val-
ues. Statistical differences were determined
by one-way analysis ofvariance followed by
Duncan's multiple range test to determine
which means were significantly different
from each other or from controls. In all
cases, ap<0.05 was used as thestatistical cri-
terion to determine significantdifferences.
Results
All groups were observed twice a day for
survival/lethality for a period of 14 days. A
100% survival was observed in the groups
that did not receive CLC (groups I and III)
while a 100% mortality was noted in the
groups that received TA followed by CLC
(groups II and IV). All the deaths occurred
between 4 and 6 days.
Serum ALT and SDH were estimated
as markers of liver injury over a time
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Figure 2. Serum sorbitol dehydrogenase (SDH)
was measured as a marker of liver injury over a
time course (0-96 hr) following each treatment
(treatment protocol as in Fig. 1). Results are
expressed as mean ± SE for four rats in each
group ateach time point. Numbers above the error
bars indicate significant differences from control
(O hr) and 150 mg/kg TA treated groups, respec-
tively(p.0.05). Control SDH value:78 U/mI.
course of0-96 hr after treatment with 150
mg TA/kg. Figures 1 and 2 show the ALT
and SDH activities at various times after
the administration of TA in the presence
and the absence of CLC treatment. In the
group receiving 150 mg/kg TA alone, ALT
activity increased up to 48 hr and then
declined to normal, indicating an initial
infliction of injury followed by recovery;
this is consistent with 100% animal sur-
vival. Colchicine intervention significantly
altered the course of these biochemical
events. Marked progression of injury, as
indicated by significantly higher elevation
of serum ALT, was evident from 48 hr
onward. This progression of injury was
associated with 100% animal mortality in
this group. Sorbitol dehydrogenase eleva-
tion measured in a similar fashion exhibit-
ed the same trend (Fig. 2).
The liver sections stained by H&E were
examined for necrotic cells, extent of
inflammation, and neutrophil infiltration.
Swollen cells and a few pyknotic nuclei
started appearing around the centrilobular
region between 6 and 12 hr in the rats
treated with 150 mg/kg TA. Pericentral
hepatocellular necrosis was clearly evident
at 12 hr and was progressive between 12
and 24 hr. Periportal cells remained unaf-
fected. Moderate centrilobular necrosis
observed in the 150 mg/kg TA treated
group progressively declined between 24
and 48 hr. Centrilobular damage accompa-
nied by extensive neutrophil infiltration
was evident between 36 and 48 hr. In
sharp contrast, CLC treatment resulted in
marked centrilobular necrosis at 36 hr.
This was associated with extensive neu-
trophil infiltration and vacoulation.
Between 48 and 72 hr, progression of
injury was accelerated as evidenced by
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widespread necrosis, crumbling centrilobu-
lar columns, and damaged portal tracts. By
96 hr, fulminant liver injury with no zonal
specificity was observed, indicating com-
plete destruction ofthe liver architecture.
3H-T incorporation into hepatonuclear
DNA over a time course (0-96 hr) follow-
ing the administration of 150 mg/kg TA
alone and over 36-96 hr following treat-
ment with TA + CLC, measured as a mark-
er of S-phase stimulation, is represented in
Figure 3. Peak 3H-T incorporation after the
administration of 150 mg/kg TA occurred
between 36 and 48 hr. Administration of
CLC (1 mg/kg, ip) resulted in a significant
reduction of S-phase stimulation (Fig. 4).
This suppression sustained until 96 hr and
ultimately resulted in 100% animal death.
Examination of the H&E-stained sections
revealed a significant mitotic activity in the
rats treated with 150 mg/kg TA alone
between 36 and 72 hr in sharp contrast to
no mitotic activity in the rats receiving TA
and CLC. Thus, timely stimulation of tis-
sue repair was consistent with animal sur-
vival while suppression ofrepair activity led
to a dramatic reversal of events leading to
100% animal lethality.
The results ofthymidine incorporation
were further corroborated by the PCNA
immunohistochemical procedure (Figs. 5,
6). Normally, most cells in the liver are in
the resting phase (Go; Fig. 5A), and a
small proportion ofcells are in other phas-
es ofthe cell cycle. After administration of
TA (150 mg/kg), cell cycle progression is
stimulated; this results in a large number
of cells in the G1 phase by 24 hr and S-
phase between 36 and 48 hr. The maxi-
Figure 3. Representative liver histopathology during a time course after thioacetamide treatment. Top panel represents photomicrographs of liver sections from
rats receiving 150 mg/kg TA taken at 36 hr, 48 hr, and 72 hr after treatment. Bottom panel represents photomicrographs of liver sections from rats receiving 150
mg/kg TA+CLC at36 hr, 48 hr, and 72 hr. c, central vein; p, pyknotic nuclei; v,vacuolization; n, areas ofnecrosis;f, fibrosis; m, mitosis.
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mum number ofS-phase cells seen by this
method is in agreement with S-phase stim-
ulation observed by 3H-T incorporation.
Most ofthe cells progress to the G2 phase
between 36 and 48 hr. The maximum
number ofcells are seen in the M-phase at
the 48 hr. By 96 hr the liver returned to
normal quiescence as evidenced by the
predominant number ofGo cells. In sharp
contrast, CLC intervention blocked the
Go-G1 transition and thereafter arrested
the progression of the cell cycle. S-phase
synthesis and mitotic activity were ablated
almost completely. Progression of the cell
cycle and timely stimulation of tissue
repair were consistent with animal sur-
vival, while ablation of the repair process
by colchicine intervention led to unre-
strained progression of injury and culmi-
nated in 100% animal mortality from an
otherwise nonlethal and moderately toxic
dose; this indicates that stimulated cell
division and tissue repair are key events in
the outcome oftoxicity.
Discussion
Earlier studies haveamplydemonstrated that
tissue repair is a biological response that
accompanies chemical-induced injury (13-19,30). Other studies (11,13,14,22,
31-36) indicate that the G2-subpopulation of cells in the liver undergo mitosis after
treatment with lowdoses oftoxicants such as
thioacetamide, galactosamine, dichloroben-
zene, CHCI3 or CC14. Additionally, several
investigators (37-41) have observed that
newly divided cells are significantly more
W
Figure 5. Results of the proliferating cell nuclear antigen study after intraperitoneal treatment with 150 mg/kg TA+vehicle and 150 mg/kg TA+CLC (1 mg/kg). Representative photomicrographs of liver sections from rats at36 hr, 48 hr, and 72 hr after 150 mg/kg TA+vehicle treatment and 36 hr, 48 hr and 72 hr after 150 mg TA/kg+CLC treatment. Go' cells with blue nuclear staining; G1, cells with light-brown nuclear staining; S, cells with deep brown nuclear staining; G2, cells with or without speckled nuclear staining and with diffused cytoplasmic staining; M, cells with diffuse cytoplasmic and deep blue chromosomal staining. Significant S- phase stimulation at36 and 48 hrfollowing 150 mg/kg TA is contrasted with inhibited S-phase stimulation with 150 mg/kg TA+CLC.
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resistant to cytotoxic effects ofa variety of
toxic chemicals. Using TA as a model com-
pound, we have also reported that the repair
response can be measured in a dose-depen-
dent and temporal manner in parallel with
injury (19). The toxicodynamic interaction
between tissue repair and injury in a
dose-response paradigm and its effect on the
ultimate outcome of toxicity has major
implications. Measuring the parallel but
opposing biological responses of repair and
injury may provide new insights on the use
ofdose-response relationships in predictive
toxicologyandriskassessment.
The objective ofthis study was to sub-
ject the concept that stimulated tissue
repair plays a critical role in the ultimate
outcome ofTA toxicity to further experi-
mental scrutiny in a dose-response para-
digm. We hypothesized that if stimulated
cell division and tissue repair were indeed
the mechanism of animal survival, then
intervention with the repair mechanism
should convert nonlethal doses into lethal
doses. To test this hypothesis, we chose
two doses (150 and 300 mg/kg) of TA, a
model hepatotoxicant. These two doses
cause moderate injury but are nonlethal by
virtue of their ability to maximally stimu-
latehepatocellular division and tissue repair
(19). CLC (1 mg/kg) was used as an
antimitotic tool to block stimulated cell
division and tissue repair. Earlier studies
have demonstrated that CLC used in this
dose does not disrupt hepatobiliary func-
tion (20,21).
Alethality studywas designed (Table 1)
to investigate the effect of colchicine treat-
ment. It should be noted that 150 and 300
mg/kg TA are otherwise nonlethal in the
absence of CLC treatment. While liver
injury occurs, simultaneous dose-related
stimulation ofcell division and tissue repair
allows the animals to overcome this injury
and survive. However, a 100% lethality was
observed in the presence ofCLC treatment
in both the groups. For further mechanistic
inquiry, we chose the 150 mg/kg TA dose.
Liver injury and tissue repair were the two
parallel but opposing responses measured
and were used as predictors ofregression or
progression ofliver injuryleading to animal
recoveryordeath, respectively.
Serum enzyme (ALT, SDH) elevation
andliver histopathology (Figs. 1, 2, 3) were
used as indices ofliver injury following the
administration of 150 mg/kg TA both in
the presence and absence ofCLC interven-
tion over a time course of 0-96 hr and
36-96 hr, respectively. In the absence of
CLC treatment, a moderate elevation of
serum enzyme was observed between 24
and 48 hr. Thereafter, the animals recov-
ered from liver injury, as evidenced by the
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Figure 4. 3H-T into hepatonuclear DNA after TA
treatment. 3H-T (35 pCi) was administered 2 hr
prior to sacrifice at each time point. One group
received CLC (1 mg/kg, ip) at 30 hr and 42 hr fol-
lowing administration of 150 mg/kg TA. The other
group received normal saline (1 ml/kg) at the
same time points. Results are expressed as mean
± SE for four rats at each time point. Number
above error bars represents significant differ-
ences from control (0 hr) and 150 mg/kg TA treat-
ed groups, respectively (p.0.05). Control 3H-T
value = 150 dpm/pg DNA.
prompt decline ofenzyme activity between
72 and 96 hr to control level (Figs. 1, 2).
In contrast, CLC treatment resulted in a
dramatic progression ofinjury as indicated
by progressive elevation of serum enzyme
activity between 48 and 96 hr. Under a
light microscope, liver sections revealed
identical injury in both groups at 36 hr
(Fig. 3). Thereafter, injury progressed
remarkably between 36 and 96 hr in the
rats receiving CLC after 150 mg/kg TA, as
evidenced by severe centrilobular necrosis,
vacuolation, and congestion; injury
regressed in the rats receiving 150 mg/kg
TA alone. An interesting observation here
is that the 36 hr injury was not significant-
ly different between the CLC-treated and
CLC-nontreated groups. This indicates
that the inflictive phase ofliver injury from
TAwas not affected by CLC treatment.
Tissue repair indicated by the S-phase
DNAsynthesis and PCNA assay (Figs. 4, 5,
6) explains the dichotomy between the out-
comes of TA treatment with or without
CLC. Following the administration of the
150 mg/kg TA alone, there is a peak and
sustained H-T incorporation into hepa-
tonuclear DNA between 36 and 48 hr (Fig.
4). These rapidly dividing cells form new
resilient hepatic parenchymal cells that con-
tinuously replace the dead cells, thereby
restoring hepatolobular architecture and
function. Consequently, injury is not only
restrained from progression, liver structure
and function are restored which eliminates
liver injury altogether between 48 and 72
hr. In contrast, CLC treatment results in an
ablation of this compensatory mechanism
as shown byblocked S-phase stimulation, as
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Figure 6. Graphical representation of cell cycle
progression as measured by proliferating cell
nuclear antigen immunohistochemical procedure.
Percentage was calculated from a total of 1000
viewed cells in the centrilobular region ofthe liver
for each animal. Each time point had four rats per
group. Rats received a single dose of 150 mg/kg
TA or 150 mg/kg TA+CLC, intraperitoneally.
Percent cells in different phases of cell cycle
were then counted during a time course of 0-96
hr. *, significant difference from control; t, signifi-
cant difference between groups (p.0.05). Control
rats received vehicle only (normal saline, 1 ml/kg,
intraperitoneally).
well as cell cycle progression. Failure in the
timely appearance of an adequate number
ofnew cells allows unrestrained progression
ofinjury on the one hand and deteriorating
hepatic structure and function on the other,
leading to lethality from an otherwise non-
lethal dose. It should be noted that, only
after failure of cell division to occur, the
progressive phase of injury flares in the
group that receives CLC.
These findings have the potential to
affect current risk assessment and predictive
toxicology methods. A knowledge of the
mechanisms of infliction of injury by toxic
chemicals has given us the ability to predict
with a degree ofconfidence that a particular
chemical or physical agent will or will not
inflict tissue injury under a given set of
exposure circumstances. However, that the
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ultimate outcome of the injury is deter-
mined by the initiation of timely and ade-
quate tissue repair calls for a clearer under-
standing ofthe underlying biology to attain
greater precision in predictive toxicology.
These findings have two broad implica-
tions. First, an increased understanding of
the biological events that follow infliction
of injury (toxicodynamic phase) helps to
bridge the link between mechanisms
responsible for the injury (Stage I) and the
ultimate outcome of that injury (Stage II)
(42). Secondly, the finding that the repair
response can be manipulated and that such
manipulation leads to a complete reversal
in the outcome of toxic injury opens up
avenues for therapeutic applications in the
realm ofbiomedicine.
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